CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort

[1]  Marilyn M. Li,et al.  Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. , 2020, Cancer cell.

[2]  F. Ducray,et al.  PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas , 2019, Neuro-Oncology.

[3]  F. Ducray,et al.  CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. , 2019, Neuro-oncology.

[4]  M. Kool,et al.  Integrated molecular characterization of IDH‐mutant glioblastomas , 2018, Neuropathology and applied neurobiology.

[5]  T. Pietsch,et al.  MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma , 2018, Clinical Neuroradiology.

[6]  Konstantinos J. Mavrakis,et al.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.

[7]  L. Klein-Hitpass,et al.  Supratentorial ependymomas of childhood carry C11orf95–RELA fusions leading to pathological activation of the NF-κB signaling pathway , 2014, Acta Neuropathologica.

[8]  Li Ding,et al.  C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.

[9]  P. Lichter,et al.  Molecular staging of intracranial ependymoma in children and adults. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Lichter,et al.  Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma , 2009, Genes, chromosomes & cancer.

[11]  D. Schiffer,et al.  CDKN2A/p16 in ependymomas , 2001, Journal of Neuro-Oncology.

[12]  D. Brat,et al.  Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. , 2001, The American journal of pathology.